MIDD in Early Oncology Clinical Development: Dose Optimization

Home  /  Resources  /  White Paper  /  MIDD In Early Oncology Clinical Development : Dose Optimization & Beyond

MIDD In Early Oncology Clinical Development : Dose Optimization & Beyond

MIDD In Early Oncology Clinical Development

Dose optimization is a necessary method to ensure patients receive the appropriate amount of medicine and an important consideration as part of a long development process. By leveraging Model-Informed Drug Development (MIDD), dose optimization creates a path to keeping oncology clinical trials on pace from an early stage.

Download the Whitepaper

Request a Proposal

Additional Resources

Proactive Cohort Management for Mastering Dose Escalation in Early-Phase Development

Webinar

Proactive Cohort Management for Mastering Dose Escalation in Early-Phase Oncology Development

Learn More
FDA Project Optimus

Blog

FDA’s Project Optimus and the Shift in Dose Selection for Oncology Therapeutics: An Update

Learn More

Expert Conversations

FDA Project Optimus and Dose Optimization: Putting Guidance into Practice in Oncology Trials

Learn More

View All Resources

Partner With the A-Team

Let us know how we can help you bring new therapies to light. Get in touch to get started.

Schedule a Consultation

Join the A-Team

Want to help small and mid-size biopharma companies change the therapeutic landscape?

View Open Jobs

Subscribe to our monthly newsletter